logo

For the Inventor, By the Inventor

Ballerup, Denmark

Leo-Pharma A/s


USPTO Granted Patents = 67

% Expired Patents = 49.3



Trademarks = 29

Forward Citations = 196

Loading Chart...
Loading Chart...

112 inventors (with patents filed for the assignee):

goldMedal Karsten Petersson (10 out of 10 patents)

silverMedal Simon Feldbæk Nielsen (10 out of 13 patents)

bronzeMedal Jens Munk Hansen (8 out of 19 patents)

4.  Marianne Lind (8 out of 8 patents)

5.  Gritt Rasmussen (8 out of 8 patents)

6.  Mette Rydahl Sonne (8 out of 9 patents)

7.  Xifu Liang (7 out of 17 patents)

8.  Jakob Felding (7 out of 31 patents)

9.  Mogens Larsen (5 out of 5 patents)

10.  Patrick Stephen Johnson (5 out of 5 patents)

11.  Simon Feldbaek Nielsen (5 out of 22 patents)

12.  Anne Marie Horneman (5 out of 9 patents)

13.  Bjarne Nørremark (5 out of 8 patents)

14.  Daniel Rodriguez Greve (5 out of 14 patents)

15.  Kevin Neil Dack (4 out of 4 patents)


Core Competencies:
JAK Inhibitors
Phosphodiesterase Inhibitors
Vitamin D Analogues
Small Molecule Modulators
Heterocyclic Compounds
Protein Tyrosine Kinase Inhibitors
Neurokinin Receptor Antagonists
Corticosteroid Compositions
Crystalline Antibiotic Substances
Calcium Sensing Receptor Modulators
Topical Compositions
Triazolopyridines

67 patents:

1. 12195481 - Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof (2025-01-14),
2. 12065429 - Small molecule modulators of IL-17 (2024-08-20),
3. 12043669 - IL-1 receptor accessory protein-inhibiting antibodies and antigen-binding fragments thereof (2024-07-23),
4. 11673900 - Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof (2023-06-13),
5. 11377425 - Small molecule modulators of IL-17 (2022-07-05),
6. 11065257 - Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors (2021-07-20),
7. 10934282 - Heteroaromatic modulators of the retinoid-related orphan receptor gamma (2021-03-02),
8. 10906915 - Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors (2021-02-02),
9. 10851116 - Bicyclic amines as novel JAK kinase inhibitors (2020-12-01),
10. 10799507 - 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors (2020-10-13),
11. 10793580 - Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors (2020-10-06),
12. 10716799 - Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid (2020-07-21),
13. 10703751 - Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof (2020-07-07),
14. 10688108 - Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid (2020-06-23),
15. 10682364 - Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid (2020-06-16),
Leo Pharma A/S is a global pharmaceutical company headquartered in Ballerup, Denmark, specializing in the development and manufacturing of innovative treatments for skin diseases and other medical conditions. The company focuses on advanced therapeutic areas, particularly in dermatology and immunology, leveraging core technologies such as JAK inhibitors, phosphodiesterase inhibitors, and vitamin D analogues. Leo Pharma is dedicated to improving patient outcomes through research and the development of effective pharmaceutical compounds.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Leo-Pharma A/s
67 Patents

#6 in Ballerup

#53 in Denmark

#11,018 in the World

Ballerup, DK
Ballerup, Denmark

Leo-Pharma A/s

Forward Citations = 196

112 inventors:

goldMedal Karsten Petersson (10 out of 10 patents)

silverMedal Simon Feldbæk Nielsen (10 out of 13 patents)

bronzeMedal Jens Munk Hansen (8 out of 19 patents)

4.  Marianne Lind (8 out of 8 patents)

5.  Gritt Rasmussen (8 out of 8 patents)

Please report any incorrect information to [email protected]
Loading…